Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04220229 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04220229 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 6 participants.
The verdict
NCT04220229, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- DRUG Cabozantinib S-malate
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04220229
The ClinicalTrials.gov registry entry for NCT04220229 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib S-malate is the first listed.
NCT04220229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04220229 about?
NCT04220229 is a clinical study titled "Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities". This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving c...
What is the current status of trial NCT04220229?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-06-01. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT04220229?
The interventions under investigation include: Cabozantinib S-malate (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04220229?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.